AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25269991 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% arginine and calcium carbonate desensitizing paste (test group)
Number of subjects: 50
Study 25269991 — intervention group
Group type: COMPARATOR
Intervention: Fluoride-free prophylaxis paste (control group)
Number of subjects: 50
Study 23697466 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo drink (presumed effective antiemetic)
Number of subjects: 96
Study 23697466 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drink)
Number of subjects: 96
Study 22003000 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans sodium crocetinate (TSC) at doses above 1.00 mg/kg
Number of subjects: 48
Study 22003000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 18069698 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (peginterferon alfa‐2a, 180 mg/week, or peginterferon alfa‐2b, 1.5 mg/kg/week, plus ribavirin, 1000‐1200 mg/day) for 48 weeks
Number of subjects: 696
Study 18069698 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable treatment (peginterferon alfa‐2a, 180 mg/week, or peginterferon alfa‐2b, 1.5 mg/kg/week, plus ribavirin, 1000‐1200 mg/day) for individualized duration based on HCV RNA negativity at weeks 4, 8, or 12
Number of subjects: 696
Study 18069698 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment for patients who first achieved undetectable HCV RNA at weeks 4, 8, or 12
Number of subjects: 696
Study 18069698 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable treatment for patients who first achieved undetectable HCV RNA at weeks 4, 8, or 12
Number of subjects: 696
Study 18069698 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment duration of 48 weeks versus 24 weeks for RVR patients with baseline viremia >or=400,000 IU/mL
Number of subjects: 696
Study 16545523 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar fusion with posterior transpedicular screws
Number of subjects: 60
Study 16545523 — intervention group
Group type: COMPARATOR
Intervention: Cognitive intervention and exercises
Number of subjects: 60
Study 11948034 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA), 800 mg/d oral suspension for 8 weeks
Number of subjects: 145
Study 11948034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 9500751 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (42 microg twice daily for 12 weeks)
Number of subjects: 506
Study 7895755 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk formula B (26% oleic acid, 0.5% DHA, 0.12% AA)
Number of subjects: 0
Study 7895755 — intervention group
Group type: COMPARATOR
Intervention: Milk formula A (13% oleic acid, <0.05% AA, no DHA)
Number of subjects: 0
Study 7895755 — intervention group
Group type: COMPARATOR
Intervention: Breast milk
Number of subjects: 0
Study 2634218 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine Retard
Number of subjects: 0
Study 2634218 — intervention group
Group type: COMPARATOR
Intervention: Acebutolol
Number of subjects: 0
Study 785936 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (AMCA)
Number of subjects: 244
Study 785936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 6454366 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfentanil (0.00015, 0.0003, 0.0006 mg/kg)
Number of subjects: 1
Study 6454366 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.100, 0.150, 0.200 mg/kg)
Number of subjects: 1
Study 6454366 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (not specified dosage)
Number of subjects: 1
Study 6454366 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfentanil
Number of subjects: 1
Study 6454366 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfentanil, Morphine, Fentanyl
Number of subjects: 1
Study 30707002 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean-EVs
Number of subjects: 10
Study 30707002 — intervention group
Group type: EXPERIMENTAL
Intervention: MetS-EVs
Number of subjects: 10
Study 27860526 — intervention group
Group type: EXPERIMENTAL
Intervention: MED ID survey (two-item survey)
Number of subjects: 126
Study 27860526 — intervention group
Group type: EXPERIMENTAL
Intervention: MED ID scores ≥8 points
Number of subjects: 126
Study 27477289 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody-mediated blockade of CD47 and targeting of CD271+ melanoma cells
Number of subjects: 0
Study 27477289 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 24806481 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic warnings (GWs) designed by the FDA
Number of subjects: 1169
Study 24806481 — intervention group
Group type: COMPARATOR
Intervention: No-label control
Number of subjects: 1169
Study 21878579 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib dosed at 3 mg/kg bid
Number of subjects: 152
Study 21878579 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib dosed at 6 mg/kg bid
Number of subjects: 152
Study 21878579 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg bid capsule (or sprinkles) for patients weighing 10 to 25 kg
Number of subjects: 152
Study 21878579 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg bid for patients >25 kg
Number of subjects: 152
Study 18925413 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of salbutamol
Number of subjects: 8
Study 18925413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 17985057 — intervention group
Group type: EXPERIMENTAL
Intervention: FASTPlaque-Response (phage-based test)
Number of subjects: 0
Study 17985057 — intervention group
Group type: COMPARATOR
Intervention: Conventional drug susceptibility testing (DST)
Number of subjects: 0
Study 17985057 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin-resistant strains
Number of subjects: 0
Study 15718314 — intervention group
Group type: EXPERIMENTAL
Intervention: pegfilgrastim 6 mg subcutaneously on day 2 of each 21-day chemotherapy cycle
Number of subjects: 928
Study 12523681 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure measurement
Number of subjects: 87
Study 12523681 — intervention group
Group type: COMPARATOR
Intervention: Office blood pressure measurement
Number of subjects: 87
Study 12523681 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between home and office readings
Number of subjects: 87
Study 12523681 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning and afternoon blood pressure measurements
Number of subjects: 87
Study 10455832 — intervention group
Group type: EXPERIMENTAL
Intervention: SCOTI device
Number of subjects: 132
Study 10455832 — intervention group
Group type: COMPARATOR
Intervention: Clinical auscultatory method
Number of subjects: 132
Study 10455832 — intervention group
Group type: COMPARATOR
Intervention: Capnograph
Number of subjects: 132
Study 7596183 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy protocol adapted from the multicentre German study
Number of subjects: 74
Study 2087879 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 103-HgR vaccine (5 x 10^8 viable organisms)
Number of subjects: 50
Study 2087879 — intervention group
Group type: COMPARATOR
Intervention: E. coli K-12 placebo
Number of subjects: 50
Study 620478 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chlormethiazole
Number of subjects: 0
Study 620478 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous chlormethiazole
Number of subjects: 0
Study 31498682 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P10 (rituximab biosimilar)
Number of subjects: 0
Study 31498682 — intervention group
Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 0
Study 28826192 — intervention group
Group type: EXPERIMENTAL
Intervention: Pridopidine 45 mg twice daily (BID)
Number of subjects: 0
Study 28826192 — intervention group
Group type: EXPERIMENTAL
Intervention: Pridopidine 45 mg BID
Number of subjects: 0
Study 26125298 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDR 3D algorithm
Number of subjects: 2
Study 26125298 — intervention group
Group type: COMPARATOR
Intervention: FBP algorithm
Number of subjects: 2
Study 22926634 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrument designed to identify risk factors for non-adherence to self-management behaviors
Number of subjects: 636
Study 22926634 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite variable levels representing the highest number of self-management non-adherence risk factors
Number of subjects: 636
Study 21324028 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer of melanocytes and epidermal cells using the sandpaper method combined with dermabrasion
Number of subjects: 11
Study 21324028 — intervention group
Group type: COMPARATOR
Intervention: Simple dermabrasion
Number of subjects: 11
Study 19144760 — intervention group
Group type: EXPERIMENTAL
Intervention: Avosentan (5, 10, 25, and 50 mg)
Number of subjects: 286
Study 19144760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 17551149 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma CRP level (highest quintile)
Number of subjects: 27919
Study 17551149 — intervention group
Group type: COMPARATOR
Intervention: Baseline plasma CRP level (lowest quintile)
Number of subjects: 27919
Study 14998845 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination regimen of doxorubicin and docetaxel (60 mg/m2 each)
Number of subjects: 123
Study 14998845 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating regimen of doxorubicin and docetaxel (100 mg/m2 DOC and 75 mg/m2 doxorubicin)
Number of subjects: 123
Study 14998845 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential regimen of doxorubicin and docetaxel (100 mg/m2 DOC and 75 mg/m2 doxorubicin)
Number of subjects: 123
Study 14998845 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination regimen with prophylactic oral ciprofloxacin
Number of subjects: 123
Study 14998845 — intervention group
Group type: COMPARATOR
Intervention: Combination regimen (60 mg/m2 each)
Number of subjects: 123
Study 11773919 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 65
Study 11773919 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed myocardium (TMPG 0/1) or delayed myocardial perfusion (TMPG 2)
Number of subjects: 65
Study 9688483 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrapping of the legs
Number of subjects: 82
Study 9688483 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 82
Study 9688483 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevation of the legs
Number of subjects: 82
Study 7862935 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 200 mg per day for 4 weeks
Number of subjects: 8
Study 7862935 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo for 4 weeks
Number of subjects: 8
Study 7862935 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 200 mg per day
Number of subjects: 8
Study 2816246 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of droperidol I.V. (n = 19)
Number of subjects: 130
Study 2816246 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of droperidol I.V. (n = 30)
Number of subjects: 130
Study 2816246 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of droperidol I.V. (n = 32)
Number of subjects: 130
Study 2816246 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (2 ml) (n = 49)
Number of subjects: 130
Study 824860 — intervention group
Group type: EXPERIMENTAL
Intervention: amilorid (10 mg daily, orally) for two days
Number of subjects: 12
Study 824860 — intervention group
Group type: COMPARATOR
Intervention: potassium canrenoate (200 mg daily, i.v.) for two days
Number of subjects: 12
Study 824860 — intervention group
Group type: EXPERIMENTAL
Intervention: amilorid (10 mg daily) long-term treatment (up to 14 weeks)
Number of subjects: 12
Study 824860 — intervention group
Group type: EXPERIMENTAL
Intervention: spironolactone (200 mg daily) long-term treatment (up to 14 weeks)
Number of subjects: 12
Study 824860 — intervention group
Group type: EXPERIMENTAL
Intervention: chlortalidone (50 mg daily) long-term treatment (up to 14 weeks)
Number of subjects: 12
Study 29377736 — intervention group
Group type: EXPERIMENTAL
Intervention: Family members' heroin use status
Number of subjects: 2446
Study 29377736 — intervention group
Group type: EXPERIMENTAL
Intervention: Family support of MMT
Number of subjects: 2446
Study 29377736 — intervention group
Group type: EXPERIMENTAL
Intervention: Family problems
Number of subjects: 2446
Study 29095958 — intervention group
Group type: EXPERIMENTAL
Intervention: Friendship networks
Number of subjects: 14010
Study 29095958 — intervention group
Group type: EXPERIMENTAL
Intervention: Family networks
Number of subjects: 14010
Study 29095958 — intervention group
Group type: EXPERIMENTAL
Intervention: Photo networks
Number of subjects: 14010
Study 29095958 — intervention group
Group type: EXPERIMENTAL
Intervention: Group networks
Number of subjects: 14010
Study 25051389 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month multicomponent physical activity (PA) and fundamental movement skills (FMS) intervention
Number of subjects: 460
Study 25051389 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 460
Study 23997364 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg tiagabine
Number of subjects: 14
Study 23997364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 21958795 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive-enhanced closure with Kryptonite biocompatible adhesive
Number of subjects: 55
Study 21958795 — intervention group
Group type: COMPARATOR
Intervention: Conventional wire closure
Number of subjects: 55
Study 18245765 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity varied resistance (HV)
Number of subjects: 67
Study 18245765 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant resistance (ST)
Number of subjects: 67
Study 18245765 — intervention group
Group type: COMPARATOR
Intervention: Nontraining control (CO)
Number of subjects: 67
Study 16750452 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 145 mg with ezetimibe 10 mg
Number of subjects: 18
Study 16750452 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate 145 mg alone
Number of subjects: 18
Study 16750452 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe 10 mg alone
Number of subjects: 18
Study 14636761 — intervention group
Group type: EXPERIMENTAL
Intervention: OrCel
Number of subjects: 2
Study 14636761 — intervention group
Group type: COMPARATOR
Intervention: Biobrane-L
Number of subjects: 2
Study 10762192 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐Aminopyridine (4‐AP)
Number of subjects: 12
Study 10762192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8557900 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 150 mg
Number of subjects: 126
Study 8557900 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 100 mg
Number of subjects: 126
Study 8557900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 1794819 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin eyedrops applied at 1-h intervals for at least 10 hours
Number of subjects: 50
Study 1794819 — intervention group
Group type: COMPARATOR
Intervention: Half-strength povidone-iodine solution applied for 2 minutes
Number of subjects: 50
Study 6349444 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg daily for 6 weeks)
Number of subjects: 6
Study 6349444 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (increased dosage)
Number of subjects: 6
Study 6349444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31549456 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact force (CF) sensing ablation (TactiCath), 57% with optimal CF (≥90% lesion with ≥10g of CF)
Number of subjects: 279
Study 31549456 — intervention group
Group type: COMPARATOR
Intervention: Ablation without CF measurement
Number of subjects: 279
Study 31549456 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal CF
Number of subjects: 279
Study 31549456 — intervention group
Group type: COMPARATOR
Intervention: Ablation without CF
Number of subjects: 279
Study 30580725 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study 30580725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28691952 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 29
Study 25662699 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI+SVCI
Number of subjects: 100
Study 25662699 — intervention group
Group type: COMPARATOR
Intervention: PVI alone
Number of subjects: 100
Study 24119734 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential interferon alpha‐1b (IFNa‐1b) for 6 months
Number of subjects: 20
Study 24119734 — intervention group
Group type: COMPARATOR
Intervention: Telbivudine (LdT) treatment continued for an additional 6 months
Number of subjects: 20
Study 21904013 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey-coated dressing (Group A)
Number of subjects: 67
Study 21904013 — intervention group
Group type: COMPARATOR
Intervention: Silver-coated dressing (Group B)
Number of subjects: 67
Study 21904013 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (honey and silver dressings)
Number of subjects: 67
Study 19445374 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine fetoscopic surgical treatment using a 2-mm endoscope and diode laser fiber, performed under local anesthesia, through a single 3-mm trocard.
Number of subjects: 0
Study 19445374 — intervention group
Group type: COMPARATOR
Intervention: Serial amnioreduction
Number of subjects: 0
Study 17033544 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized tailored brief advice
Number of subjects: 1139
Study 17033544 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1139
Study 14649785 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-change (self-care manual plus eight fortnightly sessions of cognitive behavioural therapy)
Number of subjects: 28
Study 14649785 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (16 weekly sessions)
Number of subjects: 28
Study 14649785 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Guided self-change and CBT)
Number of subjects: 28
Study 10783405 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric lavage
Number of subjects: 10
Study 10783405 — intervention group
Group type: COMPARATOR
Intervention: Control (no gastric lavage)
Number of subjects: 10
Study 8999458 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) administered intravenously at a dose of 50 U/kg body mass
Number of subjects: 7
Study 8999458 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (6 subjects: 4 males and 2 females)
Number of subjects: 7
Study 8434742 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of fentanyl at a rate of 50 micrograms.h‐1 with additional epidural boluses (25 micrograms) as required
Number of subjects: 43
Study 8434742 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia using a 25 microgram epidural bolus of fentanyl with a 15 min lock‐out period
Number of subjects: 43
Study 8434742 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of patient-controlled analgesia and continuous infusion
Number of subjects: 43
Study 8434742 — intervention group
Group type: COMPARATOR
Intervention: Nurse-administered analgesia (implied control)
Number of subjects: 43
Study 2957210 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg CM 57755
Number of subjects: 16
Study 2957210 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g CM 57755
Number of subjects: 16
Study 2957210 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g CM 57755
Number of subjects: 16
Study 2957210 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg cimetidine
Number of subjects: 16
Study 2957210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30372111 — intervention group
Group type: COMPARATOR
Intervention: Contrast condition (between-category comparisons)
Number of subjects: 0
Study 30372111 — intervention group
Group type: EXPERIMENTAL
Intervention: Match condition (same-category comparisons)
Number of subjects: 0
Study 26211531 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training based physical activity program with weekly discussions on health and quality of life (Mental group)
Number of subjects: 45
Study 26211531 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training based physical activity program (Physical activity group)
Number of subjects: 45
Study 26211531 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 45
Study 24330490 — intervention group
Group type: EXPERIMENTAL
Intervention: iRoot BP
Number of subjects: 24
Study 24330490 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA
Number of subjects: 24
Study 24502374 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention that challenged beliefs about the effectiveness of various quit methods
Number of subjects: 245
Study 24502374 — intervention group
Group type: COMPARATOR
Intervention: No-intervention controls
Number of subjects: 245
Study 22179532 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month DAPT
Number of subjects: 1443
Study 22179532 — intervention group
Group type: COMPARATOR
Intervention: 12-month DAPT
Number of subjects: 1443
Study 22179532 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month DAPT (in diabetic patients)
Number of subjects: 1443
Study 22179532 — intervention group
Group type: COMPARATOR
Intervention: 12-month DAPT (in diabetic patients)
Number of subjects: 1443
Study 20378585 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg ENDD
Number of subjects: 40
Study 20378585 — intervention group
Group type: COMPARATOR
Intervention: 0 mg ENDD (placebo)
Number of subjects: 40
Study 20378585 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorette nicotine inhalator
Number of subjects: 40
Study 20378585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes
Number of subjects: 40
Study 18055721 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial ablation
Number of subjects: 237
Study 18055721 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 237
Study 16075692 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisis experience in individuals with SPMI
Number of subjects: 0